Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- (-) Low-Value Care
- (-) Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 60 Results
NPC in Health Affairs: It's Time to Talk COVID-19 Treatment Prices
In an article on the Health Affairs Blog, National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois considers questions about COVID-19 treatments and prices and lays out a roadmap to…
Will the Pandemic Provide the Push for Positive Change?
NPC President and CEO Dan Leonard considers the COVID-19 pandemic and its impact on our health care system, as well as whether we’ll see continued innovation in how we access, administer and pay for…
Underestimating the Value of an Intervention – The Case for Including Productivity in Value Assessments and Formulary Design
Research shows that including non-health care costs like productivity in value assessment frameworks can change the value assessment of interventions, impact on coverage decisions and subsequent…
Valuing Innovation in the Current and Post-Pandemic World
Biopharmaceutical industry experts gathered for a panel discussion at the eyeforpharma Virtual Conference to explore how the value of innovation, productivity and preparedness might change as a…
New National Alliance Report Encourages Inclusion of Employer-Relevant Elements in Value Assessment
The National Alliance of Healthcare Purchaser Coalitions' report evaluated existing value frameworks and offers insights on the relationship between value assessment tools and the employer…
In Social Distancing, Finding Closeness in Community
In a video, National Pharmaceutical Council President and CEO Dan Leonard discusses social distancing and the importance of community during the COVID-19 pandemic.
A Conversation About Cystic Fibrosis, Caregiving and Innovation
Lisa Yourman, the mother of two adult children living with cystic fibrosis and the Coalition Chair for Action CF, discusses how advances in medicine and technology are making a difference for her…
QALY Remains a Challenge, Societal Perspective Presents an Opportunity With ICER’s 2020 Value Assessment Framework
NPC evaluates the extent to which ICER's 2020-2023 value assessment framework addresses needed changes.
Women Matter in Value Assessments
Sarah Wells Kocsis explains why the Society for Women's Health Research is calling on the Institute for Clinical and Economic Review to ensure its value frameworks and assessments “reflect factors…
Value Assessments Should Encompass More Than Just Medicines
NPC submitted comments to the Institute for Clinical and Economic Review in response to its request for non-drug assessment topics, noting that value assessments should encompass more than just…
Concerns Raised About ICER’s Adapted Value Assessment Methods for High-Impact ‘Single and Short-term Therapies’
NPC outlines concerns with ICER's final adaptations to its value assessment framework for use when reviewing curative therapies.
Current Landscape: Value Assessment Frameworks
This report analyzed seven existing U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework.
NPC Analysis Compares, Contrasts 7 U.S. Value Assessment Frameworks
The National Pharmaceutical Council (NPC) today released an analysis of seven U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework…
Are Value Assessment Frameworks Ready for Prime Time?
An analysis from NPC, published in Value in Health, examined efforts from three organizations actively conducting value assessments.
As Value Assessments Evolve, Are They Ready for Prime Time?
This peer-reviewed study examined the evolution of the value assessment landscape in the United States.
NPC in AJMC: Why We Need Multiple Measures of Cost-Effectiveness in the US
In an editorial for The American Journal of Managed Care, NPC Chief Science Officer and Executive Vice President Dr. Robert Dubois explores the pitfalls of assigning only one organization the…
Rethinking Our Approach to Value Assessment to Ensure the Patient Voice is Heard
According to a panel at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Summit 2018 and summarized this week in Value in Health, even though value assessment frameworks…
NPC Outlines Ways to Make ICER’s Value Assessment Framework More Patient-Centered
NPC submitted comments to the Institute for Clinical and Economic Review (ICER) on ways to improve its value assessment framework and ensure that patient concerns are better addressed in treatment…
Access to Care: Development of a Medication Access Framework for Quality Measurement
A new framework, developed by the Pharmacy Quality Alliance (PQA) and supported by the National Pharmaceutical Council (NPC), identified seven main areas patients encounter while seeking access to…
Personalized Medicine in a World of Value Frameworks
In a commentary published in the Journal of Clinical Pathways, NPC's Dr. Robert W. Dubois explores how to improve value frameworks’ approach to personalized medicine.